Mentor Capital, Inc. Speaks on Cancer Investment with Long Island Investment Banking Group   

(For Immediate Release SEPTEMBER 30, 2009) 

SAN DIEGO,  Mentor Capital, Inc. (Pink Sheets:MNTR) CEO, Chet Billingsley, presented an update of Mentor Capital's rapid progress in advancing its cancer immunotherapy efforts  before the Long Island Investment Banking Group.  The gathered investment bankers and brokers represented approximately $2 Billion in Assets Under Management and are a major conduit for emerging companies to access the brokerage community. 

Mr. Billingsley highlighted the sea change in cancer treatment coming from the immunotherapy sector, which was validated  by Dendreon's (DNDN) positive FDA announcement and 1,000% stock rise in March 2009.  Both Dendreon, for prostate cancer, and Mentor Capital, for breast cancer,  use the same dendritic immunotherapy approach, only with different target cancer surface proteins.  In cancer immunotherapy, instead of chemotherapy, surgeries and radiation, the body’s  own immune system is triggered to attack cancer cells.  Patients report only flu-like symptoms as their now activated natural defenses attempt to eradicate or stabilize the targeted cancers. 

Both Dendreon and Mentor Capital are prominent in the Cancer Immunotherapy Index.  The CI Index is  projected to experience an 1100% growth if the total sector projected value keeps pace with the projected sector revenue.   

Mentor Capital is a major investor in the Florida based private company, Quantum Immunologics, now in Phase I/II FDA trials for their breast cancer immunotherapy treatment.  Additional information on Mentor Capital, and Quantum Immunologics may be referenced at the company website: www.MentorCapital.com.      

Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.   

For further information contact:  

Chet Billingsley, CEO 

Mentor Capital, Inc. 

P.O. Box 1709 

Ramona, CA  92065